Evolus, Inc. (EOLS)

Evolus's stock price has decreased by 39.75% over the past six months, with a 52-week range between $5.13 and $17.12. In Q2 2025, the company reported a net loss of $(17) million on revenues of $69.4 million, leading to a negative market reaction. In Q3 2025, Evolus announced total net revenue of $69.0 million, with an EPS of ($0.14), beating analyst estimates, but revenue missed expectations. Mizuho lowered its price target on Evolus from $20.00 to $19.00 in December 2025, while Needham & Company LLC restated a "hold" rating. In December 2025, CEO David Moatazedi sold 10,539 shares of the company's stock for approximately $75,353.85.

While Q3 is typically a seasonally lower quarter for the aesthetics market, Evolus reported that its global Jeuveau performance in Q3 2025 reflected healthy demand and sequential revenue growth, outperforming typical seasonal trends. The company also anticipates favorable seasonality to work in its favor in Q4.

Evolus, Inc. is a performance beauty company in the cash-pay aesthetic market, focusing on developing and commercializing innovative aesthetic treatments. Its major products include Jeuveau, a botulinum toxin type A formulation for frown lines, and Evolysse and Estyme, a collection of injectable hyaluronic acid gels. Evolysse was launched in the U.S. in Q2 2025, and Estyme is planned for a broader European launch in the first half of 2026.

Evolus, Inc. delivers its products in the United States, Canada, Europe, and Australia. In Europe, its neurotoxin product Nuceiva is available in markets such as Great Britain, Germany, Austria, Italy, and France. The company's principal executive offices are located in Irvine, California, USA.

Evolus positions itself as a "performance beauty company" with a customer-centric approach and a modern, digital-first strategy. The successful launch of the Evolysse dermal filler line in Q2 2025 marked Evolus's transition into a multi-product company, enhancing its competitive position. The Evolus Rewards consumer loyalty program has been a central growth driver, fueling repeat use and brand engagement. Evolus has demonstrated strong market penetration, achieving an estimated U.S. neurotoxin market share of 14% year-to-date through Q3 2025. Analyst sentiment towards Evolus has been generally positive, with a consensus recommendation of "Moderate Buy".

Evolus, Inc.'s ownership structure includes institutional, retail, and individual investors, with institutional investors holding a significant portion, approximately 52.85% to 64.51%. Major institutional owners include Nantahala Capital Management, LLC, Tang Capital Management Llc, BlackRock, Inc., Caligan Partners LP, Vanguard Group Inc, Frazier Life Sciences Management, L.P., Millennium Management Llc, State Street Corp, and Perceptive Life Sciences Master Fund, Ltd. Medytox Inc. is the largest individual Evolus shareholder, owning 10.64 million shares, representing 16.42% of the company.